Innate Pharma (IPHA) — Free Cash Flow Generation Index
Latest as of June 2024:
0.91x
Innate Pharma (IPHA) has a Free Cash Flow Generation Index of 0.91x as of June 2024. Free cash flow of $2.75 Million represents 1% of operating cash flow ($3.04 Million). See IPHA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
0.91x
Free Cash Flow / Operating CF
Free Cash Flow
$2.75 Million
USD
Operating Cash Flow
$3.04 Million
USD
Capital Expenditures
$283.00K
USD
Innate Pharma Free Cash Flow Generation Index (2006–2019)
Historical FCF Generation Index trend for Innate Pharma across 4 annual periods. Explore cash flow to debt ratio of Innate Pharma to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for Innate Pharma (2006–2019)
Year-by-year Free Cash Flow Generation Index for Innate Pharma. For the full company profile including market capitalisation, see IPHA market cap.
| Year | FCG Index | Free Cash Flow (USD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2019 | -0.87x | $-30.48 Million | $34.92 Million | $65.40 Million | ▼ -190.5% |
| 2015 | 0.96x | $200.51 Million | $207.91 Million | $7.40 Million | ▼ -1.1% |
| 2011 | 0.98x | $12.66 Million | $12.99 Million | $322.00K | ▲ +189.6% |
| 2006 | -1.09x | $-392.00K | $360.00K | $752.00K | — |
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).